ImmunityBio, Inc. (IBRX) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Richard Gerald Adcock	President, Chief Executive Officer & Director	1.58M	1969
Regan J. Lauer	Chief Accounting Officer	522,490	1970
David C. Sachs	Chief Financial Officer	902,174	1978
Patrick Soon-Shiong FRCS	Founder, Executive Chairman and Global Chief Scientific & Medical Officer	1.15M	1953
Enrique Diloné	Chief Technology Officer	0	1967
Leonard S. Sender	Chief Medical Officer of Liquid Tumors & Cell Therapy	0	N/A
Manju Saxena	Senior Vice President of Product Development & Cell Therapy Program	0	N/A
Sandeep K. Reddy	Chief Medical Officer	0	N/A
Sarah Singleton	Chief Communications Officer & Head of Patient Advocacy	0	N/A
Barry J. Simon	Chief Corporation Affairs Officer & Director	0	1965
Hans Georg Klingemann	Chief Science Officer of Cellular	0	1950
Emily Arison	Senior Vice President of Human Resources	0	N/A

Name

Title

Pay

Year Born

Richard Gerald Adcock

President, Chief Executive Officer & Director

1.58M

1969

Regan J. Lauer

Chief Accounting Officer

522,490

1970

David C. Sachs

Chief Financial Officer

902,174

1978

Patrick Soon-Shiong FRCS

Founder, Executive Chairman and Global Chief Scientific & Medical Officer

1.15M

1953

Enrique Diloné

Chief Technology Officer

1967

Leonard S. Sender

Chief Medical Officer of Liquid Tumors & Cell Therapy

N/A

Manju Saxena

Senior Vice President of Product Development & Cell Therapy Program

N/A

Sandeep K. Reddy

Chief Medical Officer

N/A

Sarah Singleton

Chief Communications Officer & Head of Patient Advocacy

N/A

Barry J. Simon

Chief Corporation Affairs Officer & Director

1965

Hans Georg Klingemann

Chief Science Officer of Cellular

1950

Emily Arison

Senior Vice President of Human Resources

N/A

Description

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.